Read time: 2:30 mins
Find out what our experts opinions are on the future of HRMS.
To address questions raised in our Quantitative HRMS Spotlight and to investigate how the field has progressed over the last two years, key figures from pharma, CROs, biotech and academia share with us their experiences and thoughts on HRMS, giving our members a 360° opinion piece. Find out what Bertrand Rochat (University of Lausanne) thinks in this interview.
To address questions raised in our Quantitative HRMS Spotlight and to investigate how the field has progressed over the last two years, key figures from pharma, CROs, biotech and academia share with us their experiences and thoughts on HRMS, giving our members a 360° opinion piece. Find out what Ian Edwards (Waters Corporation) thinks in this interview.
To address questions raised in our Quantitative HRMS Spotlight and to investigate how the field has progressed over the last two years, key figures from pharma, CROs, biotech and academia share with us their experiences and thoughts on HRMS, giving our members a 360° opinion piece. Find out what Diego Cortes (PPD) thinks in this interview.
Read time: 1:45 mins
Tandem MS vs HRMS – can you have one without the other? Find out what our experts think.
Read time: 1:45 mins
Are there any other challenges or limitations that interfere with our experts’ work that HRMS could assist with? Find out in this section of ‘Ask the experts’.
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.
In this ‘Ask the Experts’ feature we will be discussing what is required to gain approval for a biosimilar.
In this ‘Ask the Experts’ feature we will be discussing the use of biosimilars with a number of leading experts across the field. The series will explore the role of biosimilars, address the benefits and challenges of creating them and how they have gained momentum within the pharmaceutical industry.
Ask the Experts: Arno Kromminga
